The burden of acute pancreatitis on COVID-19 in the United States

• Published in: Annals of gastroenterology 2023-03, Vol.36 (2), p.208-215
• Main Authors: Chaudhry, Hunza, Sohal, Aalam, Kohli, Isha, Dukovic, Dino, Sharma, Raghav, Singla, Piyush, Hu, Bing, Prajapati, Devang, Yang, Juliana
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1108-7471; 1792-7463; 1792-7463
• DOI: 10.20524/aog.2023.0782

Although SARS-CoV-2 primarily affects the respiratory system, gastrointestinal symptoms were also seen. Our study analyzed the prevalence and impact of acute pancreatitis (AP) on COVID-19 hospitalizations in the United States. The 2020 National Inpatient Sample database was used to identify patients with COVID-19. The patients were stratified into 2 groups based on the presence of AP. AP as well as its impact on COVID-19 outcomes were evaluated. The primary outcome was in-hospital mortality. Secondary outcomes were intensive care unit (ICU) admissions, shock, acute kidney injury (AKI), sepsis, length of stay, and total hospitalization charges. Univariate and multivariate logistic/linear regression analyses were performed. The study population comprised 1,581,585 patients with COVID-19, from which 0.61% of people had AP. Patients with COVID-19 and AP had a higher incidence of sepsis, shock, ICU admissions, and AKI. On multivariate analysis, patients with AP had higher mortality (adjusted odds ratio [aOR] 1.19, 95% confidence interval [CI] 1.03-1.38; P=0.02). We also noted a higher risk of sepsis (aOR 1.22, 95%CI 1.01-1.48; P=0.04), shock (aOR 2.09, 95%CI 1.83-2.40; P